- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07365995
Um Ensaio de Fase III de BNT324 Versus Docetaxel no Cancro da Próstata Metastático Resistentes à Castração
Um Estudo de Fase III, Randomizado, de Acesso Aberto de BNT324 Versus Docetaxel com Prednisona/Prednisolona no Cancro da Próstata Metastático Resistentes à Castração
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicines prednisone or prednisolone). The study will include participants with mCRPC that have been previously treated with androgen receptor pathway inhibitor, but with no previous taxane-based systematic chemotherapy for mCRPC.
The main goals of this study are:
- To find out if BNT324 helps participants live longer without their cancer getting worse (radiographic progression-free survival [rPFS]).
- To find out if BNT324 helps participants live longer overall (overall survival [OS]).
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
The study consists of a screening period (up to 28 days), a treatment period with 21-day cycles, and an after-treatment period that includes a 30-day safety follow-up period and a long-term survival follow-up period.
Treatment continues until the cancer clearly gets worse (in scans, based on blinded independent central review [BICR] assessment or investigator's decision), side effects become unacceptable, the participant chooses to stop, or the study ends.
Participants are put into one of two groups in a 1:1 ratio, which means they will have an equal chance to be in either treatment group, i.e., BNT324 group, or docetaxel plus prednisone/prednisolone group (current SoC). An independent committee will help ensure participant safety, by regularly reviewing safety and early results.
For each participant, the treatment and follow-up periods are projected to be up to ~58 months.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: BioNTech clinical trials patient information
- Número de telefone: +49 6131 9084
- E-mail: patients@biontech.de
Locais de estudo
-
-
-
Dresden, Alemanha, 01307
- Recrutamento
- Universitätsklinikum Carl Gustav Carus
-
Halle, Alemanha, 06120
- Recrutamento
- Universitätsklinikum Halle (Saale)
-
Hamburg, Alemanha, 22763
- Recrutamento
- Asklepios Klinik Altona
-
-
-
-
-
Adelaide, Austrália, 5000
- Recrutamento
- Cancer Research SA
-
Box Hill, Austrália, 3128
- Recrutamento
- Box Hill Hospital
-
Heidelberg, Austrália, 3084
- Recrutamento
- Austin Health
-
Southport, Austrália, 4215
- Recrutamento
- Tasman Onco Research Pty Ltd
-
-
-
-
-
Porto Alegre, Brasil, 90560-032
- Recrutamento
- Hospital Moinhos de Vento
-
-
-
-
-
Brussels, Bélgica, 1200
- Recrutamento
- Cliniques Universitaires Saint-Luc
-
Ghent, Bélgica, 9000
- Recrutamento
- AZ Sint-Lucas Gent
-
-
-
-
-
Beijing, China, 100142
- Recrutamento
- Beijing Cancer Hospital
-
Beijing, China, 100034
- Recrutamento
- Peking University First Hospital
-
Beijing, China, 100050
- Recrutamento
- Beijing Friendship Hospital, Capital Medical University
-
Changsha, China, 410005
- Recrutamento
- The First Affiliated Hospital of Hunan Normal University
-
Chengdu, China, 610041
- Recrutamento
- West China Hospital, Sichuan University
-
Chongqing, China, 400072
- Recrutamento
- The Second Affiliated Hospital of Chongqing Medical University
-
Chongqing, China, 400030
- Recrutamento
- Chongqing Univ. Cancer Hosp.
-
Fuzhou, China, 350001
- Recrutamento
- Fujian Medical University Union Hospital
-
Guangzhou, China, 510163
- Recrutamento
- The First Affiliated Hospital of Guangzhou Medical University
-
Hangzhou, China, 310022
- Recrutamento
- Zhejiang Cancer Hospital
-
Hangzhou, China, 310016
- Recrutamento
- Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
-
Hangzhou, China, 310014
- Recrutamento
- Zhejiang Prov. People's Hosp.
-
Hefei, China, 230601
- Recrutamento
- Second Hospital of Anhui Medical University
-
Nanchang, China, 330006
- Recrutamento
- The First Affiliated Hospital of Nanchang University
-
Nanjing, China, 210008
- Recrutamento
- Nanjing Drum Tower Hospital
-
Nantong, China, 226361
- Recrutamento
- Nantong Tumor Hospital
-
Ningbo, China, 315010
- Recrutamento
- The First Affiliated Hospital of Ningbo University
-
Shanghai, China, 200032
- Recrutamento
- Shanghai Cancer Center
-
Shanghai, China, 200072
- Recrutamento
- No. 10 People's Hospital of Shanghai
-
Shanghai, China, 200032
- Recrutamento
- Zhongshan Hospital
-
Wenzhou, China, 325000
- Recrutamento
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, China, 430079
- Recrutamento
- Hubei Cancer Hospital
-
Wuhan, China, 420104
- Recrutamento
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Wuhu, China, 241001
- Recrutamento
- Yijishan Hospital of Wannan Medical College
-
Yantai, China, 264000
- Recrutamento
- Yantai Yuhuangding Hospital
-
-
-
-
-
Barcelona, Espanha, 08036
- Recrutamento
- Hospital Clínic de Barcelona
-
Madrid, Espanha, 28041
- Recrutamento
- Hospital Universitario 12 de Octubre
-
Madrid, Espanha, 28046
- Recrutamento
- Hospital Universitario La Paz
-
-
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85715
- Recrutamento
- Del Sol Research Mgmt LLC
-
-
California
-
Santa Barbara, California, Estados Unidos, 93105
- Recrutamento
- Sansum Clinic
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80012
- Recrutamento
- Rocky Mountain Cancer Centers
-
-
Florida
-
Fort Myers, Florida, Estados Unidos, 33901
- Recrutamento
- Florida Cancer Specialists- Fort Myers
-
St. Petersburg, Florida, Estados Unidos, 33701
- Recrutamento
- Florida Cancer Specialists- St. Petersburg
-
West Palm Beach, Florida, Estados Unidos, 33401
- Recrutamento
- Florida Cancer Specialists- West Palm Beach
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30318
- Recrutamento
- Piedmont Cancer Institute
-
-
Illinois
-
Niles, Illinois, Estados Unidos, 60714
- Recrutamento
- Illinois Cancer Specialists
-
Peoria, Illinois, Estados Unidos, 61615
- Recrutamento
- Illinois CancerCare PC
-
-
Maryland
-
Rockville, Maryland, Estados Unidos, 20850
- Recrutamento
- Maryland Oncology Hematology
-
-
New York
-
Albany, New York, Estados Unidos, 12206
- Recrutamento
- NYOH Albany Cancer Center
-
White Plains, New York, Estados Unidos, 10601
- Recrutamento
- White Plains Hospital
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45242
- Recrutamento
- Oncology/Hematology Care, Inc.
-
-
South Carolina
-
Myrtle Beach, South Carolina, Estados Unidos, 29572
- Recrutamento
- START Carolinas
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Recrutamento
- Tennessee Oncology
-
Nashville, Tennessee, Estados Unidos, 37203
- Recrutamento
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Estados Unidos, 78731
- Recrutamento
- Texas Oncology South Austin
-
Houston, Texas, Estados Unidos, 77024
- Recrutamento
- Texas Oncology Gulf Coast
-
Tyler, Texas, Estados Unidos, 75702
- Recrutamento
- Texas Oncology, P.A. - Tyler
-
Wichita Falls, Texas, Estados Unidos, 76310
- Recrutamento
- Texas Oncology - West Texas
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Recrutamento
- Virginia Cancer Specialists PC
-
Norfolk, Virginia, Estados Unidos, 23502
- Recrutamento
- Virginia Oncology Associates
-
-
-
-
-
Verona, Itália, 37124
- Recrutamento
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
-
-
-
Krakow, Polônia, 30-727
- Recrutamento
- Pratia MCM Krakow
-
Skorzewo, Polônia, 60-185
- Recrutamento
- Szpital AidPort
-
Sosnowiec, Polônia, 41-208
- Recrutamento
- Gyncentrum Szpital
-
Warsaw, Polônia, 02-781
- Recrutamento
- National Research Institute of Oncology - National Research Institute (NIO-PIB)
-
-
-
-
-
Cambridge, Reino Unido, CB2 0QQ
- Recrutamento
- Addenbrooke's Hospital
-
Cardiff, Reino Unido, CF14 2TL
- Recrutamento
- Velindre Cancer Centre
-
Leeds, Reino Unido, LS9 7TF
- Recrutamento
- St James's University Hospital
-
London, Reino Unido, SW3 6JJ
- Recrutamento
- Royal Marsden Hospital
-
London, Reino Unido, NW3 2QG
- Recrutamento
- Royal Free Hospital
-
Manchester, Reino Unido, M20 4BX
- Recrutamento
- The Christie Hospital
-
Newcastle upon Tyne, Reino Unido, NE7 7DN
- Recrutamento
- Freeman Hospital
-
Plymouth, Reino Unido, PL6 8DH
- Recrutamento
- Derriford Hospital
-
Southampton, Reino Unido, SO16 6YD
- Recrutamento
- Southampton General Hospital
-
Sutton, Reino Unido, SM2 5PT
- Recrutamento
- Royal Marsden Hospital
-
Torquay, Reino Unido, TQ2 7AA
- Recrutamento
- Torbay Hospital
-
Truro, Reino Unido, TR1 3LJ
- Recrutamento
- Royal Cornwall Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Key Inclusion Criteria:
-
Are male adults (defined as ≥18 years of age or of an acceptable age according to local regulations at the time of giving informed consent).
-
Must have documented progressive prostate cancer based on at least one of the following criteria:
- Serum/plasma PSA progression, by local laboratory, defined as two consecutive increases in PSA over a previous reference value, each measured sequentially at least 1 week apart. The PSA value at screening is required to be ≥1.0 ng/mL.
- Radiographic soft tissue progression as per PCWG3-modified RECIST v1.1.
- Radiographic progression of bone disease: evaluable disease or new bone lesion(s) by bone scan per PCWG3 criteria.
-
Had previously received one or two prior androgen receptor pathway inhibitor treatments and experienced disease progression during or after a minimum of 8 weeks of therapy.
-
Must not have received systemic cytotoxic chemotherapy, including taxane-based chemotherapy, for mCRPC.
-
Must have had prior orchiectomy and/or have ongoing androgen-deprivation therapy and a castrate-level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L). Participant being treated with luteinizing hormone-releasing hormone agonists or antagonists must continue such treatment throughout the study.
-
Must have an Eastern Cooperative Oncology Group performance score of 0 or 1.
Key Exclusion Criteria:
- Have received prior treatment with B7-H3 targeted therapy, including B7-H3 ADCs.
- Have uncontrolled or significant cardiovascular disease, as defined in the protocol.
- Have a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids or have current ILD/pneumonitis.
NOTE: Other protocol defined Inclusion/Exclusion criteria apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: BNT324
|
Intravenous infusion
Outros nomes:
|
|
Comparador Ativo: Docetaxel mais prednisona/prednisolona
|
Intravenous infusion Oral |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
rPFS assessed by BICR
Prazo: From randomization to end of study, i.e., up to 58 months
|
By arm. rPFS is defined as time from randomization to radiographic disease progression per Prostate Cancer Working Group 3 (PCWG3)-modified Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria, or death from any cause, whichever occurs first. |
From randomization to end of study, i.e., up to 58 months
|
|
OS
Prazo: From randomization to end of study, i.e., up to 58 months
|
By arm. OS is defined as time from randomization to death from any cause. |
From randomization to end of study, i.e., up to 58 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to first subsequent therapy (TFTS)
Prazo: From randomization to end of study, i.e., up to 58 months
|
By arm. TFST is defined as time from randomization to initiation of the first subsequent systemic anticancer therapy or death, whichever occurs first. |
From randomization to end of study, i.e., up to 58 months
|
|
Objective response rate (ORR)
Prazo: From randomization to end of study, i.e., up to 58 months
|
By arm. ORR is defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) (per PCWG3-modifed RECIST v1.1 as assessed by BICR) is observed as best overall response. |
From randomization to end of study, i.e., up to 58 months
|
|
Duration of response (DOR)
Prazo: From randomization to end of study, i.e., up to 58 months
|
By arm. DOR is defined as time from first objective response (confirmed CR or PR per PCWG3-modified RECIST v1.1 criteria as assessed by BICR) to first occurrence of objective tumor progression (progressive disease per PCWG3-modified RECIST v1.1 criteria as assessed by BICR) or death from any cause, whichever occurs first. |
From randomization to end of study, i.e., up to 58 months
|
|
Time to pain progression (TTPP)
Prazo: From randomization to safety follow-up visit (30 days after the last dose), i.e., up to 58 months
|
By arm. TTPP is defined as time from randomization to pain progression as determined by Brief Pain Inventory-Short Form Item 3 "worst pain in 24 hours" and opiate analgesic use (Analgesic Quantification Algorithm score). |
From randomization to safety follow-up visit (30 days after the last dose), i.e., up to 58 months
|
|
rPFS as assessed by investigator
Prazo: From randomization to end of study, i.e., up to 58 months
|
By arm. rPFS is defined as time from randomization to radiographic disease progression per PCWG3-modified RECIST v1.1 criteria, or death from any cause, whichever occurs first. |
From randomization to end of study, i.e., up to 58 months
|
|
Time to first symptomatic skeletal-related event (SSRE)
Prazo: From randomization to end of study, i.e., up to 58 months
|
By arm. Time to first SSRE is defined as time from randomization to first occurrence of any of the following SSREs:
|
From randomization to end of study, i.e., up to 58 months
|
|
Time to prostate-specific antigen (PSA) progression (by central lab testing results)
Prazo: From baseline to end of treatment visit, i.e., up to 58 months
|
By arm. Time to PSA progression is defined as time from randomization to PSA progression per PCWG3 criteria. |
From baseline to end of treatment visit, i.e., up to 58 months
|
|
PSA response (by central lab testing results)
Prazo: From baseline to end of treatment visit, i.e., up to 58 months
|
By arm. PSA response is defined as having a post-baseline PSA reduction ≥50% from baseline with a consecutive confirmation assessment at least 3 weeks later per PCWG3 criteria. |
From baseline to end of treatment visit, i.e., up to 58 months
|
|
Number and percentage of participants with treatment-emergent adverse events (TEAEs) including Grade ≥3, serious, and fatal TEAEs
Prazo: From the start of study treatment until 30 days after the last dose of study treatment or until start of new systemic anticancer therapy, whichever occurs first, i.e., up to 58 months
|
TEAEs by relationship and by arm. |
From the start of study treatment until 30 days after the last dose of study treatment or until start of new systemic anticancer therapy, whichever occurs first, i.e., up to 58 months
|
|
Number and percentage of participants with dose interruptions, reductions or discontinuations of study treatment due to TEAEs
Prazo: From the start of study treatment until 30 days after the last dose of study treatment or until start of new systemic anticancer therapy, whichever occurs first, i.e., up to 58 months
|
By arm. |
From the start of study treatment until 30 days after the last dose of study treatment or until start of new systemic anticancer therapy, whichever occurs first, i.e., up to 58 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: BioNTech Responsible Person, BioNTech SE
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- BNT324-03
- 2025-524445-27-00 (Ctis)
- 2025 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .